Clear Labs is a technology company.
Clear Labs has raised $155.0M across 6 funding rounds.
Clear Labs has raised $155.0M in total across 6 funding rounds.
Clear Labs is a technology company specializing in fully automated next-generation sequencing (NGS) platforms that provide turnkey diagnostics solutions primarily for genomic surveillance and food safety testing. It serves laboratories, hospitals, and food brands by translating complex genomic data into actionable insights to detect pathogens like SARS-CoV-2 variants and foodborne bacteria such as listeria and salmonella. The company addresses critical problems in public health and food safety by enabling rapid, accurate, and scalable genomic testing with automation that reduces manual labor and accelerates results[1][2][4].
Founded in 2014, Clear Labs was co-founded by Sasan Amini and Mahni Ghorashi, who leveraged their genomics expertise to pioneer applications of NGS beyond clinical settings, focusing initially on food safety to mitigate recalls and outbreaks. The company built the world’s largest molecular food database to support its testing platform and has since expanded into infectious disease surveillance, notably launching a SARS-CoV-2 whole genome sequencing solution in 2021. Clear Labs has demonstrated strong growth momentum, securing multiple funding rounds totaling over $135 million, including a $60 million Series C led by Morgan Stanley and T. Rowe Price in 2021, and achieving significant market penetration in public health labs[1][2][3][4].
Clear Labs rides the growing trend of applying next-generation sequencing and automation to public health and food safety, sectors increasingly reliant on rapid, precise genomic data to manage outbreaks and ensure product authenticity. The timing is critical as genomic sequencing costs have dropped significantly, enabling broader adoption. Market forces such as heightened regulatory scrutiny, demand for food transparency, and the COVID-19 pandemic’s emphasis on genomic surveillance have accelerated Clear Labs’ relevance. By automating complex workflows, Clear Labs influences the ecosystem by making high-throughput sequencing accessible and scalable, thereby enhancing disease surveillance and food safety standards globally[1][4].
Clear Labs is poised to expand its influence by continuing to innovate in automated genomic sequencing and analytics. Future trends likely to shape its journey include the increasing integration of AI in genomic data interpretation, expansion into new diagnostic areas such as oncology and infectious diseases beyond COVID-19, and broader adoption of genomic surveillance in public health infrastructure. As sequencing technology becomes more embedded in routine diagnostics and food safety, Clear Labs’ platform could become a standard tool for real-time pathogen monitoring and food authenticity verification, reinforcing its role as a key player in the genomics-driven diagnostics landscape[5].
In summary, Clear Labs exemplifies the convergence of genomics, automation, and data science to solve pressing challenges in health and food safety, with a strong foundation and momentum to shape the future of genomic diagnostics.
Clear Labs has raised $155.0M in total across 6 funding rounds.
Clear Labs's investors include Alumni Ventures, Andreessen Horowitz, Applied Ventures, ARCH Venture Partners, Felicis Ventures, GV, Intel Capital, Lockheed Martin Ventures, Menlo Ventures, Playground Global, Quiet Capital, The House Fund.
Clear Labs has raised $155.0M across 6 funding rounds. Most recently, it raised $30.0M Series D in January 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2025 | $30.0M Series D | Alumni Ventures, Andreessen Horowitz, Applied Ventures, ARCH Venture Partners, Felicis Ventures, GV, Intel Capital, Lockheed Martin Ventures, Menlo Ventures, Playground Global, Quiet Capital, The House Fund, Wing Venture Capital, Diego Oppenheimer, Gokul Rajaram, Yan-David Erlich | |
| May 1, 2021 | $60.0M Series C | Andreessen Horowitz, ARCH Venture Partners, Felicis Ventures, GV, Menlo Ventures, Quiet Capital, Wing Venture Capital, Diego Oppenheimer, Gokul Rajaram, Yan-David Erlich | |
| May 1, 2020 | $21.0M Venture Round | ARCH Venture Partners, Felicis Ventures, Menlo Ventures, Wing Venture Capital | |
| Oct 1, 2018 | $21.0M Series B | Alta Life Sciences, Alumni Ventures, ARCH Venture Partners, Codon Capital, Felicis Ventures, Krishna Yeshwant, Menlo Ventures, Tencent Holdings, Wing Venture Capital | |
| Dec 1, 2016 | $16.0M Series B | Felicis Ventures, Tencent Holdings, Wing Venture Capital, Vikas Sabnani | |
| Sep 1, 2015 | $7.0M Series A | Felicis Ventures, Wing Venture Capital |